Bio-Techne Key Executives
This section highlights Bio-Techne's key executives, including their titles and compensation details.
Find Contacts at Bio-Techne
(Showing 0 of )
Bio-Techne Earnings
This section highlights Bio-Techne's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2025 | 2025-02-05 | $0.38 | $0.42 |
| Read Transcript | Q1 | 2025 | 2024-10-30 | $0.38 | $0.42 |
| Read Transcript | Q4 | 2024 | 2024-08-07 | $0.49 | $0.49 |
| Read Transcript | Q3 | 2024 | 2024-05-01 | $0.46 | $0.48 |
| Read Transcript | Q2 | 2024 | 2024-02-01 | $0.42 | $0.40 |
| Read Transcript | Q1 | 2024 | 2023-10-31 | $0.44 | $0.41 |
| Read Transcript | Q4 | 2023 | 2023-08-08 | $0.55 | $0.55 |
| Read Transcript | Q3 | 2023 | 2023-05-03 | $0.53 | $0.53 |
| Read Transcript | Q2 | 2023 | 2023-02-02 | $0.49 | $0.47 |
| Read Transcript | Q1 | 2023 | 2022-11-01 | $0.59 | $0.45 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
$49.08
Stock Price
$7.76B
Market Cap
3.10K
Employees
Minneapolis, MN
Location
Financial Statements
Access annual & quarterly financial statements for Bio-Techne, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M |
| Cost of Revenue | $389.33M | $366.89M | $349.10M | $298.18M | $255.50M |
| Gross Profit | $769.73M | $769.82M | $756.50M | $632.85M | $483.19M |
| Gross Profit Ratio | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% |
| Research and Development Expenses | $96.66M | $92.49M | $87.14M | $70.60M | $65.19M |
| General and Administrative Expenses | $396.83M | $352.44M | $339.00M | $289.92M | $240.88M |
| Selling and Marketing Expenses | $- | $25.94M | $33.77M | $35.03M | $19.70M |
| Selling General and Administrative Expenses | $396.83M | $378.38M | $372.77M | $324.95M | $260.58M |
| Other Expenses | $- | $39.72M | $4.80M | $-89.12M | $119.06M |
| Operating Expenses | $563.04M | $470.87M | $459.91M | $395.55M | $325.77M |
| Cost and Expenses | $952.37M | $837.76M | $809.01M | $693.74M | $581.27M |
| Interest Income | $3.32M | $3.41M | $794.00K | $473.00K | $605.00K |
| Interest Expense | $15.74M | $11.21M | $11.31M | $13.95M | $19.20M |
| Depreciation and Amortization | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M |
| EBITDA | $310.37M | $460.56M | $420.12M | $258.47M | $373.91M |
| EBITDA Ratio | 26.78% | 40.52% | 38.00% | 27.76% | 50.62% |
| Operating Income | $206.69M | $298.94M | $296.59M | $149.55M | $74.68M |
| Operating Income Ratio | 17.83% | 26.30% | 26.83% | 16.06% | 10.11% |
| Total Other Income Expenses Net | $-21.00M | $39.72M | $4.80M | $-89.12M | $119.06M |
| Income Before Tax | $185.69M | $338.66M | $301.39M | $148.18M | $276.48M |
| Income Before Tax Ratio | 16.02% | 29.79% | 27.26% | 15.92% | 37.43% |
| Income Tax Expense | $17.58M | $53.22M | $38.29M | $8.59M | $47.18M |
| Net Income | $168.10M | $285.26M | $272.05M | $140.41M | $229.30M |
| Net Income Ratio | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% |
| EPS | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 |
| EPS Diluted | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 |
| Weighted Average Shares Outstanding | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M |
| Weighted Average Shares Outstanding Diluted | 160.77M | 161.85M | 164.12M | 161.93M | 157.60M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $297.03M | $289.46M | $306.10M | $303.43M | $272.60M | $276.94M | $301.32M | $294.15M | $271.58M | $269.65M | $288.23M | $290.38M | $269.28M | $257.72M | $259.03M | $243.55M | $224.25M | $204.20M | $175.83M | $194.68M |
| Cost of Revenue | $103.14M | $106.44M | $101.22M | $98.18M | $96.01M | $91.74M | $96.62M | $91.98M | $88.22M | $90.06M | $87.88M | $88.92M | $85.58M | $86.72M | $83.08M | $75.28M | $73.35M | $66.47M | $62.52M | $64.62M |
| Gross Profit | $193.89M | $183.02M | $204.88M | $205.25M | $176.59M | $185.19M | $204.70M | $202.16M | $183.36M | $179.59M | $200.35M | $201.46M | $183.69M | $171.00M | $175.94M | $168.27M | $150.90M | $137.73M | $113.31M | $130.06M |
| Gross Profit Ratio | 65.27% | 63.23% | 66.93% | 67.64% | 64.78% | 66.87% | 67.93% | 68.73% | 67.52% | 66.60% | 69.51% | 69.38% | 68.22% | 66.35% | 67.93% | 69.09% | 67.29% | 67.45% | 64.44% | 66.81% |
| Research and Development Expenses | $25.02M | $23.87M | $23.99M | $25.76M | $22.92M | $24.00M | $23.42M | $22.71M | $22.46M | $23.90M | $23.15M | $21.74M | $20.65M | $21.60M | $20.72M | $17.05M | $16.79M | $16.04M | $16.78M | $15.95M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $37.52M | $66.32M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $19.70M | $- |
| Selling General and Administrative Expenses | $121.45M | $119.16M | $101.90M | $107.50M | $115.67M | $105.33M | $86.75M | $99.24M | $93.01M | $99.38M | $96.63M | $89.27M | $100.69M | $86.17M | $86.64M | $82.60M | $83.12M | $72.60M | $57.22M | $66.32M |
| Other Expenses | $- | $- | $689.00K | $-874.00K | $810.00K | $-6.30M | $-6.21M | $-15.00K | $-1.46M | $47.40M | $-1.52M | $-21.68M | $23.83M | $4.16M | $-61.47M | $-23.27M | $5.37M | $-9.75M | $22.22M | $-970.00K |
| Operating Expenses | $146.47M | $143.03M | $125.89M | $133.27M | $138.58M | $129.33M | $110.17M | $121.95M | $115.47M | $123.28M | $119.78M | $111.01M | $121.34M | $107.78M | $107.36M | $99.65M | $99.91M | $88.64M | $74.00M | $82.27M |
| Cost and Expenses | $249.61M | $249.47M | $227.11M | $231.45M | $234.59M | $221.07M | $206.79M | $213.94M | $203.69M | $213.34M | $207.66M | $199.93M | $206.93M | $194.50M | $190.45M | $174.93M | $173.26M | $155.11M | $136.52M | $146.89M |
| Interest Income | $1.35M | $926.00K | $905.00K | $712.00K | $816.00K | $890.00K | $1.03M | $974.00K | $968.00K | $433.00K | $188.00K | $168.00K | $245.00K | $193.00K | $167.00K | $114.00K | $78.00K | $114.00K | $119.00K | $144.00K |
| Interest Expense | $2.15M | $2.18M | $2.51M | $4.00M | $4.33M | $4.89M | $3.70M | $15.00K | $2.36M | $3.79M | $2.50M | $2.49M | $2.90M | $3.41M | $3.29M | $2.66M | $3.58M | $4.42M | $4.62M | $4.49M |
| Depreciation and Amortization | $27.08M | $28.14M | $28.06M | $27.31M | $27.80M | $28.54M | $26.92M | $26.97M | $26.70M | $26.64M | $25.87M | $25.37M | $25.10M | $24.73M | $24.67M | $21.10M | $20.88M | $21.09M | $20.99M | $21.11M |
| EBITDA | $72.11M | $73.86M | $96.76M | $99.33M | $77.94M | $84.08M | $110.39M | $105.85M | $103.00M | $85.72M | $86.53M | $111.81M | $92.99M | $87.17M | $38.95M | $91.53M | $76.32M | $70.32M | $84.73M | $68.58M |
| EBITDA Ratio | 24.28% | 25.52% | 31.61% | 32.74% | 28.59% | 30.36% | 36.63% | 35.99% | 37.93% | 31.79% | 30.02% | 38.51% | 34.53% | 33.83% | 15.04% | 37.58% | 34.03% | 34.44% | 48.19% | 35.23% |
| Operating Income | $47.42M | $39.99M | $78.99M | $71.98M | $38.00M | $55.86M | $94.53M | $80.21M | $67.89M | $56.32M | $80.57M | $90.45M | $62.35M | $63.22M | $68.58M | $68.63M | $50.99M | $49.09M | $39.31M | $47.79M |
| Operating Income Ratio | 15.96% | 13.81% | 25.81% | 23.72% | 13.94% | 20.17% | 31.37% | 27.27% | 25.00% | 20.88% | 27.95% | 31.15% | 23.15% | 24.53% | 26.48% | 28.18% | 22.74% | 24.04% | 22.36% | 24.55% |
| Total Other Income Expenses Net | $-4.54M | $184.00K | $-4.16M | $-5.91M | $-4.62M | $-6.30M | $-6.21M | $-15.00K | $-1.46M | $47.40M | $-1.52M | $-21.68M | $23.83M | $4.16M | $-61.47M | $-23.27M | $5.37M | $-9.75M | $22.21M | $-970.00K |
| Income Before Tax | $42.88M | $40.17M | $41.66M | $61.08M | $33.39M | $49.56M | $88.32M | $80.20M | $66.43M | $103.72M | $79.05M | $68.77M | $86.18M | $67.38M | $7.11M | $45.35M | $56.37M | $39.34M | $61.53M | $46.82M |
| Income Before Tax Ratio | 14.43% | 13.88% | 13.61% | 20.13% | 12.25% | 17.90% | 29.31% | 27.26% | 24.46% | 38.46% | 27.43% | 23.68% | 32.00% | 26.15% | 2.75% | 18.62% | 25.14% | 19.27% | 34.99% | 24.05% |
| Income Tax Expense | $7.99M | $6.57M | $1.07M | $12.03M | $5.92M | $-1.44M | $12.83M | $9.98M | $16.42M | $13.98M | $17.14M | $8.63M | $14.12M | $-1.60M | $-7.53M | $-48.00K | $10.22M | $5.94M | $2.68M | $10.39M |
| Net Income | $34.89M | $33.60M | $40.59M | $49.06M | $27.46M | $50.99M | $75.48M | $70.22M | $50.01M | $89.56M | $61.52M | $60.74M | $80.17M | $69.61M | $14.96M | $45.78M | $46.27M | $33.40M | $58.85M | $36.43M |
| Net Income Ratio | 11.75% | 11.61% | 13.26% | 16.17% | 10.08% | 18.41% | 25.05% | 23.87% | 18.41% | 33.21% | 21.35% | 20.92% | 29.77% | 27.01% | 5.78% | 18.80% | 20.63% | 16.35% | 33.47% | 18.71% |
| EPS | $0.22 | $0.21 | $0.26 | $0.31 | $0.17 | $0.32 | $0.48 | $0.45 | $0.32 | $0.57 | $0.39 | $0.39 | $0.51 | $0.45 | $0.10 | $0.29 | $0.30 | $0.22 | $0.38 | $0.24 |
| EPS Diluted | $0.22 | $0.21 | $0.25 | $0.31 | $0.17 | $0.31 | $0.47 | $0.43 | $0.31 | $0.55 | $0.38 | $0.37 | $0.49 | $0.42 | $0.09 | $0.28 | $0.29 | $0.21 | $0.37 | $0.23 |
| Weighted Average Shares Outstanding | 158.43M | 158.53M | 157.87M | 157.31M | 157.53M | 158.13M | 157.50M | 157.31M | 157.01M | 156.93M | 156.81M | 157.09M | 157.24M | 156.38M | 155.63M | 155.42M | 154.76M | 154.14M | 153.22M | 153.21M |
| Weighted Average Shares Outstanding Diluted | 160.63M | 161.12M | 160.65M | 160.50M | 160.06M | 161.94M | 161.92M | 161.62M | 161.75M | 162.17M | 163.59M | 163.88M | 164.83M | 164.63M | 163.80M | 162.70M | 161.03M | 160.10M | 158.80M | 157.74M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $151.79M | $180.57M | $172.57M | $199.09M | $146.62M |
| Short Term Investments | $1.07M | $23.74M | $74.46M | $32.46M | $124.27M |
| Cash and Short Term Investments | $152.86M | $204.31M | $247.03M | $231.55M | $270.89M |
| Net Receivables | $241.39M | $218.47M | $194.55M | $145.38M | $122.53M |
| Inventory | $179.73M | $171.64M | $141.12M | $116.75M | $103.15M |
| Other Current Assets | $43.43M | $27.07M | $22.86M | $16.92M | $24.34M |
| Total Current Assets | $617.42M | $621.48M | $605.56M | $510.61M | $520.92M |
| Property Plant Equipment Net | $342.44M | $324.53M | $288.80M | $281.74M | $248.29M |
| Goodwill | $972.66M | $872.74M | $822.10M | $843.07M | $728.31M |
| Intangible Assets | $507.08M | $534.64M | $531.52M | $615.97M | $516.54M |
| Goodwill and Intangible Assets | $1.48B | $1.41B | $1.35B | $1.46B | $1.24B |
| Long Term Investments | $252.15M | $-88.98M | $36.03M | $-93.12M | $-101.09M |
| Tax Assets | $- | $88.98M | $98.99M | $93.12M | $101.09M |
| Other Non-Current Assets | $12.12M | $285.30M | $-88.19M | $11.57M | $13.52M |
| Total Non-Current Assets | $2.09B | $2.02B | $1.69B | $1.75B | $1.51B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B |
| Account Payables | $37.97M | $25.68M | $33.87M | $29.38M | $23.09M |
| Short Term Debt | $25.84M | $22.40M | $36.36M | $35.70M | $31.57M |
| Tax Payables | $3.71M | $12.02M | $13.24M | $5.34M | $2.38M |
| Deferred Revenue | $27.93M | $23.07M | $23.41M | $19.00M | $13.05M |
| Other Current Liabilities | $63.94M | $45.34M | $69.15M | $62.87M | $44.45M |
| Total Current Liabilities | $159.38M | $128.51M | $176.02M | $152.28M | $106.67M |
| Long Term Debt | $406.62M | $443.77M | $301.54M | $396.45M | $411.49M |
| Deferred Revenue Non-Current | $- | $1.53M | $2.09M | $25.40M | $199.00K |
| Deferred Tax Liabilities Non-Current | $- | $88.98M | $98.99M | $93.12M | $101.09M |
| Other Non-Current Liabilities | $69.02M | $99.90M | $116.23M | $142.99M | $128.24M |
| Total Non-Current Liabilities | $475.64M | $543.67M | $417.78M | $539.44M | $539.73M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $635.02M | $672.18M | $593.79M | $691.72M | $646.40M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.58M | $1.58M | $392.00K | $390.00K | $385.00K |
| Retained Earnings | $1.33B | $1.31B | $1.12B | $1.09B | $1.06B |
| Accumulated Other Comprehensive Income Loss | $-78.32M | $-66.06M | $-75.20M | $-57.29M | $-97.20M |
| Other Total Stockholders Equity | $820.34M | $721.54M | $653.66M | $534.41M | $420.54M |
| Total Stockholders Equity | $2.07B | $1.97B | $1.70B | $1.57B | $1.38B |
| Total Equity | $2.07B | $1.97B | $1.70B | $1.58B | $1.38B |
| Total Liabilities and Stockholders Equity | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B |
| Minority Interest | $- | $- | $-759.00K | $8.26M | $- |
| Total Liabilities and Total Equity | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B |
| Total Investments | $253.22M | $23.74M | $74.46M | $32.46M | $124.27M |
| Total Debt | $419.54M | $454.96M | $325.97M | $420.55M | $433.53M |
| Net Debt | $267.75M | $274.39M | $153.40M | $221.46M | $286.90M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $177.55M | $187.54M | $151.79M | $139.91M | $130.13M | $148.66M | $180.57M | $127.28M | $164.68M | $165.26M | $172.57M | $160.82M | $211.84M | $196.32M | $199.09M | $186.14M | $165.53M | $169.40M | $146.62M | $156.22M |
| Short Term Investments | $- | $- | $1.07M | $5.40M | $5.52M | $- | $23.74M | $29.91M | $32.07M | $37.82M | $74.46M | $70.35M | $67.14M | $38.74M | $32.46M | $90.11M | $117.43M | $117.99M | $124.27M | $104.87M |
| Cash and Short Term Investments | $177.55M | $187.54M | $152.86M | $145.31M | $135.65M | $148.66M | $204.31M | $157.20M | $196.76M | $203.07M | $247.03M | $231.17M | $278.98M | $235.06M | $231.55M | $276.24M | $282.95M | $287.39M | $270.89M | $261.09M |
| Net Receivables | $217.94M | $223.69M | $241.39M | $227.89M | $207.45M | $204.57M | $218.47M | $216.41M | $184.76M | $174.17M | $194.55M | $202.09M | $152.90M | $147.55M | $145.38M | $157.79M | $128.24M | $122.64M | $122.53M | $117.45M |
| Inventory | $188.37M | $185.04M | $179.73M | $179.50M | $180.84M | $186.08M | $171.64M | $169.46M | $160.23M | $150.01M | $141.12M | $128.28M | $121.86M | $117.37M | $116.75M | $109.99M | $106.59M | $106.00M | $103.15M | $99.67M |
| Other Current Assets | $50.78M | $52.30M | $43.43M | $57.95M | $66.70M | $52.16M | $27.07M | $27.92M | $23.43M | $24.77M | $22.86M | $31.56M | $36.50M | $43.77M | $16.92M | $22.58M | $24.15M | $25.86M | $24.34M | $13.71M |
| Total Current Assets | $634.64M | $648.57M | $617.42M | $610.65M | $590.64M | $591.48M | $621.48M | $571.00M | $565.18M | $552.03M | $605.56M | $593.11M | $590.23M | $543.75M | $510.61M | $566.61M | $541.93M | $541.89M | $520.92M | $491.93M |
| Property Plant Equipment Net | $335.14M | $343.16M | $342.44M | $340.99M | $335.07M | $333.96M | $324.53M | $321.55M | $307.79M | $293.84M | $288.80M | $281.85M | $276.11M | $278.53M | $281.74M | $270.81M | $263.76M | $261.69M | $248.29M | $238.76M |
| Goodwill | $964.61M | $982.59M | $972.66M | $970.97M | $980.08M | $969.38M | $872.74M | $870.54M | $869.59M | $865.42M | $822.10M | $827.62M | $832.06M | $840.02M | $843.07M | $746.46M | $746.67M | $731.64M | $728.31M | $725.83M |
| Intangible Assets | $461.05M | $486.00M | $507.08M | $526.43M | $550.61M | $578.97M | $534.64M | $553.26M | $567.65M | $585.53M | $531.52M | $551.34M | $569.35M | $596.30M | $615.97M | $489.18M | $504.17M | $507.59M | $516.54M | $530.33M |
| Goodwill and Intangible Assets | $1.43B | $1.47B | $1.48B | $1.50B | $1.53B | $1.55B | $1.41B | $1.42B | $1.44B | $1.45B | $1.35B | $1.38B | $1.40B | $1.44B | $1.46B | $1.24B | $1.25B | $1.24B | $1.24B | $1.26B |
| Long Term Investments | $256.35M | $256.31M | $252.15M | $260.01M | $249.73M | $-83.13M | $-88.98M | $268.03M | $15.79M | $16.68M | $36.03M | $-99.30M | $-101.42M | $-98.81M | $275.00K | $-98.40M | $-105.34M | $-101.37M | $-101.09M | $-96.18M |
| Tax Assets | $- | $- | $109.32M | $63.67M | $71.58M | $83.13M | $88.98M | $94.61M | $111.38M | $112.92M | $-36.03M | $99.30M | $101.42M | $98.81M | $86.88M | $98.40M | $105.34M | $101.37M | $101.09M | $96.18M |
| Other Non-Current Assets | $18.64M | $19.39M | $12.12M | $-51.54M | $-46.95M | $281.58M | $285.30M | $-79.28M | $-73.98M | $-75.71M | $46.83M | $45.98M | $37.11M | $11.59M | $-75.58M | $11.59M | $11.34M | $10.28M | $13.52M | $12.17M |
| Total Non-Current Assets | $2.04B | $2.09B | $2.20B | $2.11B | $2.14B | $2.16B | $2.02B | $2.03B | $1.80B | $1.80B | $1.69B | $1.71B | $1.71B | $1.73B | $1.75B | $1.52B | $1.53B | $1.51B | $1.51B | $1.51B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $2.67B | $2.74B | $2.81B | $2.72B | $2.73B | $2.76B | $2.64B | $2.60B | $2.36B | $2.35B | $2.29B | $2.30B | $2.30B | $2.27B | $2.26B | $2.08B | $2.07B | $2.05B | $2.03B | $2.00B |
| Account Payables | $33.12M | $31.56M | $37.97M | $28.89M | $31.51M | $28.08M | $25.68M | $27.12M | $24.10M | $30.48M | $33.87M | $30.86M | $26.76M | $25.62M | $29.38M | $25.84M | $24.25M | $27.19M | $23.09M | $19.73M |
| Short Term Debt | $- | $26.97M | $25.84M | $25.96M | $25.34M | $24.40M | $22.40M | $21.45M | $21.95M | $24.23M | $36.36M | $36.23M | $36.12M | $36.50M | $35.70M | $33.33M | $32.32M | $31.89M | $31.57M | $31.59M |
| Tax Payables | $3.14M | $3.14M | $3.71M | $12.08M | $6.65M | $5.94M | $12.02M | $18.17M | $25.28M | $17.27M | $13.24M | $9.79M | $14.28M | $6.50M | $5.34M | $3.56M | $3.66M | $2.16M | $2.38M | $10.38M |
| Deferred Revenue | $- | $26.61M | $27.93M | $30.11M | $28.43M | $24.52M | $23.07M | $24.88M | $21.81M | $22.06M | $23.41M | $23.11M | $19.08M | $19.12M | $19.00M | $18.71M | $13.22M | $13.29M | $13.05M | $13.56M |
| Other Current Liabilities | $125.00M | $53.85M | $63.94M | $52.78M | $43.30M | $44.82M | $45.34M | $49.55M | $35.26M | $43.59M | $69.15M | $66.86M | $58.57M | $46.24M | $62.87M | $56.19M | $44.12M | $42.16M | $44.45M | $46.41M |
| Total Current Liabilities | $161.26M | $142.13M | $159.38M | $149.82M | $135.23M | $127.75M | $128.51M | $141.16M | $128.40M | $137.63M | $176.02M | $166.84M | $154.81M | $133.99M | $152.28M | $137.64M | $117.57M | $105.42M | $106.67M | $104.98M |
| Long Term Debt | $381.62M | $385.43M | $406.62M | $481.75M | $543.03M | $537.33M | $443.77M | $463.27M | $278.18M | $329.42M | $301.54M | $302.86M | $327.34M | $352.78M | $396.45M | $269.75M | $282.71M | $376.83M | $411.49M | $476.84M |
| Deferred Revenue Non-Current | $- | $2.59M | $2.27M | $1.89M | $1.67M | $1.28M | $1.53M | $1.62M | $1.69M | $1.94M | $5.00M | $-23.11M | $7.00M | $17.60M | $25.40M | $7.10M | $5.60M | $199.00K | $199.00K | $1.70M |
| Deferred Tax Liabilities Non-Current | $37.72M | $50.02M | $165.19M | $63.67M | $71.58M | $83.13M | $88.98M | $94.61M | $111.38M | $112.92M | $98.99M | $99.30M | $101.42M | $98.81M | $93.12M | $98.40M | $105.34M | $101.37M | $101.09M | $96.18M |
| Other Non-Current Liabilities | $11.34M | $17.20M | $69.02M | $11.56M | $17.36M | $9.39M | $99.90M | $10.97M | $18.34M | $19.60M | $116.23M | $17.57M | $18.75M | $37.65M | $142.99M | $30.91M | $31.39M | $30.18M | $128.24M | $29.75M |
| Total Non-Current Liabilities | $430.68M | $455.24M | $584.96M | $556.97M | $631.96M | $629.86M | $543.67M | $568.85M | $407.90M | $461.94M | $417.78M | $419.73M | $447.51M | $489.24M | $539.44M | $399.06M | $419.44M | $508.39M | $539.73M | $602.77M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $591.93M | $597.37M | $744.34M | $706.79M | $767.19M | $757.61M | $672.18M | $710.01M | $536.29M | $599.57M | $593.79M | $586.57M | $602.32M | $623.23M | $691.72M | $536.70M | $537.01M | $613.81M | $646.40M | $707.75M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $431.00K | $- | $- | $7.59M | $8.26M | $8.49M | $8.94M | $- | $- | $- |
| Common Stock | $- | $1.59M | $1.58M | $1.58M | $1.57M | $1.58M | $1.58M | $1.57M | $1.57M | $392.00K | $392.00K | $393.00K | $393.00K | $393.00K | $390.00K | $389.00K | $388.00K | $386.00K | $385.00K | $381.00K |
| Retained Earnings | $- | $1.34B | $1.33B | $1.30B | $1.26B | $1.33B | $1.31B | $1.25B | $1.20B | $1.16B | $1.12B | $1.13B | $1.15B | $1.12B | $1.09B | $1.09B | $1.10B | $1.07B | $1.06B | $1.01B |
| Accumulated Other Comprehensive Income Loss | $-85.65M | $-60.09M | $-78.32M | $-75.31M | $-63.66M | $-78.02M | $-66.06M | $-73.55M | $-75.12M | $-91.81M | $-75.20M | $-55.15M | $-59.47M | $-64.22M | $-57.29M | $-64.02M | $-64.24M | $-83.14M | $-97.20M | $-103.46M |
| Other Total Stockholders Equity | $2.18B | $855.97M | $820.34M | $790.42M | $764.27M | $746.61M | $721.54M | $715.05M | $700.68M | $680.06M | $653.66M | $636.32M | $616.43M | $583.85M | $534.41M | $514.30M | $481.00M | $448.68M | $420.54M | $381.63M |
| Total Stockholders Equity | $2.09B | $2.14B | $2.07B | $2.01B | $1.96B | $2.00B | $1.97B | $1.89B | $1.83B | $1.75B | $1.70B | $1.71B | $1.70B | $1.65B | $1.57B | $1.55B | $1.53B | $1.44B | $1.38B | $1.29B |
| Total Equity | $2.09B | $2.14B | $2.07B | $2.01B | $1.96B | $2.00B | $1.97B | $1.89B | $1.83B | $1.75B | $1.70B | $1.71B | $1.70B | $1.65B | $1.58B | $1.56B | $1.54B | $1.44B | $1.38B | $1.29B |
| Total Liabilities and Stockholders Equity | $2.67B | $2.74B | $2.81B | $2.72B | $2.73B | $2.76B | $2.64B | $2.60B | $2.36B | $2.35B | $2.29B | $2.30B | $2.30B | $2.27B | $2.26B | $2.08B | $2.07B | $2.05B | $2.03B | $2.00B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-759.00K | $-1.05M | $-458.00K | $7.59M | $8.26M | $8.49M | $8.94M | $- | $- | $- |
| Total Liabilities and Total Equity | $2.67B | $2.74B | $2.81B | $2.72B | $2.73B | $2.76B | $2.64B | $2.60B | $2.36B | $2.35B | $2.29B | $2.30B | $2.30B | $2.27B | $2.26B | $2.08B | $2.07B | $2.05B | $2.03B | $2.00B |
| Total Investments | $256.35M | $256.31M | $253.22M | $265.41M | $5.52M | $-83.13M | $23.74M | $29.91M | $32.07M | $37.82M | $110.49M | $70.35M | $67.14M | $38.74M | $32.46M | $90.11M | $117.43M | $117.99M | $124.27M | $104.87M |
| Total Debt | $395.13M | $398.92M | $419.54M | $494.73M | $555.70M | $549.53M | $454.96M | $473.99M | $289.16M | $341.53M | $325.97M | $327.23M | $351.64M | $377.28M | $420.55M | $292.66M | $305.12M | $399.03M | $433.53M | $498.88M |
| Net Debt | $217.58M | $211.38M | $267.75M | $354.81M | $425.57M | $400.87M | $274.39M | $346.71M | $124.48M | $176.28M | $153.40M | $166.41M | $139.80M | $180.96M | $221.46M | $106.53M | $139.59M | $229.62M | $286.90M | $342.67M |
Annual Cash Flow
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $168.07M | $285.44M | $263.10M | $139.59M | $229.30M |
| Depreciation and Amortization | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M |
| Deferred Income Tax | $-39.45M | $-29.57M | $6.82M | $-27.43M | $13.13M |
| Stock Based Compensation | $38.04M | $39.23M | $42.18M | $48.98M | $32.37M |
| Change in Working Capital | $-10.11M | $-48.19M | $-69.52M | $29.26M | $-5.25M |
| Accounts Receivables | $-20.53M | $-20.87M | $-57.60M | $-15.55M | $6.56M |
| Inventory | $-14.21M | $400.00K | $-32.01M | $-7.14M | $-14.86M |
| Accounts Payables | $25.77M | $-7.91M | $12.74M | $19.09M | $10.34M |
| Other Working Capital | $-1.13M | $-19.81M | $7.34M | $32.86M | $-7.28M |
| Other Non Cash Items | $30.71M | $-99.76M | $-18.38M | $74.02M | $-147.07M |
| Net Cash Provided by Operating Activities | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M |
| Investments in Property Plant and Equipment | $-62.88M | $-38.24M | $-44.91M | $-44.30M | $-51.74M |
| Acquisitions Net | $-169.71M | $-315.36M | $- | $-225.91M | $1.91M |
| Purchases of Investments | $-5.53M | $-20.50M | $-25.00M | $-39.68M | $-70.19M |
| Sales Maturities of Investments | $28.08M | $73.22M | $26.05M | $66.38M | $147.12M |
| Other Investing Activities | $7.00M | $35.24M | $-53.00M | $26.14M | $78.84M |
| Net Cash Used for Investing Activities | $-203.03M | $-265.65M | $-96.85M | $-243.52M | $27.09M |
| Debt Repayment | $-31.00M | $94.00M | $-85.50M | $-15.50M | $-148.50M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-80.04M | $-19.56M | $-160.95M | $-43.18M | $-50.11M |
| Dividends Paid | $-50.42M | $-50.28M | $-50.19M | $-49.62M | $-48.90M |
| Other Financing Activities | $39.06M | $-1.54M | $53.78M | $45.75M | $63.71M |
| Net Cash Used Provided by Financing Activities | $-122.40M | $22.62M | $-242.85M | $-62.55M | $-183.80M |
| Effect of Forex Changes on Cash | $-2.33M | $-3.36M | $-12.09M | $6.37M | $-2.77M |
| Net Change in Cash | $-28.78M | $8.00M | $-26.52M | $52.47M | $45.74M |
| Cash at End of Period | $151.79M | $180.57M | $172.57M | $199.09M | $146.62M |
| Cash at Beginning of Period | $180.57M | $172.57M | $199.09M | $146.62M | $100.89M |
| Operating Cash Flow | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M |
| Capital Expenditure | $-62.88M | $-38.24M | $-44.91M | $-44.30M | $-51.74M |
| Free Cash Flow | $236.10M | $216.15M | $280.36M | $307.86M | $153.47M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $34.89M | $33.60M | $40.58M | $49.05M | $27.47M | $50.99M | $75.48M | $70.22M | $50.01M | $89.73M | $61.91M | $60.14M | $72.06M | $68.98M | $14.64M | $45.40M | $46.14M | $33.40M | $58.84M | $36.43M |
| Depreciation and Amortization | $27.08M | $28.14M | $28.06M | $27.31M | $27.80M | $28.54M | $26.92M | $26.97M | $26.70M | $26.64M | $25.87M | $25.37M | $25.10M | $24.73M | $24.67M | $21.10M | $20.88M | $21.09M | $20.99M | $21.11M |
| Deferred Income Tax | $-8.08M | $-5.34M | $-9.55M | $-7.58M | $-10.72M | $-11.59M | $-6.92M | $-16.29M | $-1.60M | $-4.77M | $-1.07M | $655.00K | $1.83M | $5.41M | $-21.41M | $-6.24M | $668.00K | $-452.00K | $4.49M | $-6.16M |
| Stock Based Compensation | $14.71M | $10.18M | $7.06M | $8.13M | $12.75M | $10.09M | $-2.08M | $10.11M | $16.74M | $14.46M | $8.41M | $8.07M | $13.97M | $11.74M | $9.81M | $10.64M | $15.58M | $12.95M | $6.02M | $7.86M |
| Change in Working Capital | $9.74M | $-9.74M | $-10.24M | $1.33M | $18.78M | $2.10M | $81.53M | $-39.39M | $-17.38M | $-22.93M | $6.94M | $-34.70M | $11.77M | $-53.52M | $36.12M | $-13.33M | $11.84M | $-5.37M | $-11.03M | $-7.78M |
| Accounts Receivables | $-623.00K | $21.56M | $-17.92M | $-22.94M | $4.73M | $15.60M | $-38.20M | $-32.20M | $-5.91M | $17.34M | $3.33M | $-51.58M | $-5.71M | $-3.64M | $17.16M | $-30.38M | $-3.24M | $910.00K | $3.86M | $-7.26M |
| Inventory | $185.00K | $188.00K | $-4.62M | $-22.00K | $-4.36M | $181.00K | $-1.35M | $-10.45M | $-7.68M | $-10.69M | $-15.97M | $-7.33M | $-5.72M | $-2.98M | $-3.02M | $-3.53M | $1.38M | $-1.97M | $-4.85M | $-5.63M |
| Accounts Payables | $10.88M | $-10.91M | $18.61M | $1.78M | $8.08M | $-2.69M | $-2.26M | $5.89M | $-10.14M | $-1.40M | $1.51M | $11.40M | $2.13M | $-2.30M | $6.89M | $3.57M | $1.71M | $6.92M | $312.00K | $2.92M |
| Other Working Capital | $-707.00K | $-20.58M | $-6.31M | $22.52M | $10.33M | $-10.99M | $123.34M | $-2.63M | $6.35M | $-28.18M | $6.20M | $-38.77M | $15.36M | $-48.24M | $32.25M | $-13.37M | $8.76M | $-10.32M | $-6.49M | $-5.07M |
| Other Non Cash Items | $6.00M | $7.04M | $19.59M | $86.68M | $7.04M | $-20.75M | $-91.54M | $-1.09M | $-10.09M | $-47.06M | $7.04M | $13.60M | $-23.73M | $-8.90M | $58.19M | $17.28M | $-5.85M | $4.40M | $-34.52M | $-1.98M |
| Net Cash Provided by Operating Activities | $84.35M | $63.89M | $75.50M | $80.99M | $83.12M | $59.38M | $83.39M | $50.53M | $64.38M | $56.08M | $102.72M | $73.13M | $100.99M | $48.43M | $122.02M | $74.87M | $89.27M | $66.01M | $44.79M | $49.47M |
| Investments in Property Plant and Equipment | $-6.82M | $-9.17M | $-17.98M | $-16.44M | $-14.86M | $-13.59M | $-10.83M | $-11.75M | $-6.11M | $-9.56M | $-13.57M | $-15.10M | $-10.17M | $-6.07M | $-11.32M | $-10.60M | $-11.45M | $-10.94M | $-17.37M | $-9.28M |
| Acquisitions Net | $- | $- | $167.56M | $- | $-3.28M | $-164.28M | $-101.18M | $-130.82M | $- | $-83.36M | $-21.94M | $- | $- | $1.05M | $-215.59M | $-556.00K | $-9.77M | $- | $1.91M | $- |
| Purchases of Investments | $- | $- | $7.96M | $- | $-5.53M | $-2.43M | $20.50M | $20.50M | $14.50M | $-14.50M | $-5.00M | $-34.50M | $-11.50M | $-13.50M | $-556.00K | $-12.50M | $-945.00K | $-26.24M | $-19.46M | $-25.63M |
| Sales Maturities of Investments | $- | $1.08M | $9.17M | $-2.15M | $5.53M | $23.76M | $-29.16M | $-26.51M | $12.00M | $73.22M | $-15.00M | $13.61M | $- | $12.45M | $67.88M | $23.23M | $14.11M | $29.04M | $24.45M | $54.27M |
| Other Investing Activities | $1.79M | $-13.60M | $-175.52M | $2.15M | $-5.53M | $2.43M | $115.92M | $-92.52M | $-20.50M | $14.51M | $-5.00M | $-34.50M | $-13.50M | $-2.10M | $556.00K | $556.00K | $-10.32M | $2.80M | $6.90M | $28.64M |
| Net Cash Used for Investing Activities | $-5.03M | $-21.68M | $-8.81M | $-16.44M | $-23.67M | $-154.11M | $-4.76M | $-241.10M | $-109.00K | $-19.69M | $-18.57M | $-35.99M | $-35.17M | $-7.12M | $-226.90M | $129.00K | $-8.60M | $-8.14M | $-10.47M | $19.36M |
| Debt Repayment | $- | $-19.00M | $-70.00M | $-58.00M | $7.00M | $90.00M | $-20.00M | $170.00M | $-64.66M | $8.66M | $-3.12M | $-23.12M | $-18.12M | $-41.12M | $125.88M | $-16.12M | $-92.12M | $-33.12M | $-63.12M | $36.88M |
| Common Stock Issued | $-25.10M | $25.10M | $- | $18.33M | $- | $- | $8.41M | $- | $5.03M | $- | $- | $- | $- | $37.88M | $- | $- | $- | $- | $-51.24M | $- |
| Common Stock Repurchased | $- | $- | $-402.00K | $-168.00K | $-80.04M | $-20.23M | $-39.00K | $-11.00M | $-5.03M | $-19.56M | $-58.82M | $-60.84M | $-41.29M | $-23.25M | $-19.34M | $-43.18M | $- | $- | $- | $-50.11M |
| Dividends Paid | $-12.74M | $-12.69M | $-12.63M | $-12.58M | $-12.56M | $-12.65M | $-12.60M | $-12.58M | $-12.56M | $-12.54M | $-12.54M | $-12.58M | $-12.58M | $-12.49M | $-12.45M | $-12.45M | $-12.39M | $-12.34M | $-12.26M | $-12.28M |
| Other Financing Activities | $-71.10M | $-4.98M | $22.93M | $18.16M | $4.20M | $-5.83M | $8.38M | $-6.58M | $5.03M | $-8.36M | $8.75M | $24.32M | $37.24M | $13.93M | $4.26M | $16.52M | $14.44M | $10.53M | $30.66M | $7.73M |
| Net Cash Used Provided by Financing Activities | $-83.84M | $-11.57M | $-60.09M | $-52.42M | $-81.40M | $71.51M | $-24.22M | $150.84M | $-72.19M | $-31.81M | $-65.73M | $-84.06M | $-53.38M | $-39.68M | $117.69M | $-55.23M | $-90.08M | $-34.93M | $-44.72M | $-17.79M |
| Effect of Forex Changes on Cash | $-5.47M | $5.12M | $5.28M | $-2.35M | $3.42M | $-8.69M | $-1.13M | $2.32M | $7.34M | $-11.90M | $-6.67M | $-4.09M | $3.08M | $-4.40M | $150.00K | $842.00K | $5.54M | $-159.00K | $811.00K | $-5.12M |
| Net Change in Cash | $-9.99M | $35.75M | $11.88M | $9.78M | $-18.53M | $-31.91M | $53.29M | $-37.40M | $-575.00K | $-7.31M | $11.75M | $-51.02M | $15.52M | $-2.77M | $12.96M | $20.61M | $-3.88M | $22.78M | $-9.59M | $45.92M |
| Cash at End of Period | $177.55M | $187.54M | $151.79M | $139.91M | $130.13M | $148.66M | $180.57M | $127.28M | $164.68M | $165.26M | $172.57M | $160.82M | $211.84M | $196.32M | $199.09M | $186.14M | $165.53M | $169.40M | $146.62M | $156.22M |
| Cash at Beginning of Period | $187.54M | $151.79M | $139.91M | $130.13M | $148.66M | $180.57M | $127.28M | $164.68M | $165.26M | $172.57M | $160.82M | $211.84M | $196.32M | $199.09M | $186.14M | $165.53M | $169.40M | $146.62M | $156.22M | $110.29M |
| Operating Cash Flow | $84.35M | $63.89M | $75.50M | $80.99M | $83.12M | $59.38M | $83.39M | $50.53M | $64.38M | $56.08M | $102.72M | $73.13M | $100.99M | $48.43M | $122.02M | $74.87M | $89.27M | $66.01M | $44.79M | $49.47M |
| Capital Expenditure | $-6.82M | $-9.17M | $-17.98M | $-16.44M | $-14.86M | $-13.59M | $-10.83M | $-11.75M | $-6.11M | $-9.56M | $-13.57M | $-15.10M | $-10.17M | $-6.07M | $-11.32M | $-10.60M | $-11.45M | $-10.94M | $-17.37M | $-9.28M |
| Free Cash Flow | $77.53M | $54.72M | $57.52M | $64.55M | $68.25M | $45.79M | $72.56M | $38.79M | $58.27M | $46.52M | $89.15M | $58.03M | $90.83M | $42.36M | $110.70M | $64.26M | $77.82M | $55.07M | $27.42M | $40.19M |
Bio-Techne Dividends
Explore Bio-Techne's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
0.45%
Dividend Payout Ratio
29.99%
Dividend Paid & Capex Coverage Ratio
2.64x
Bio-Techne Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.08 | $0.08 | February 14, 2025 | February 17, 2025 | February 28, 2025 | February 05, 2025 |
| $0.08 | $0.08 | November 08, 2024 | November 11, 2024 | November 22, 2024 | October 30, 2024 |
| $0.08 | $0.08 | August 19, 2024 | August 19, 2024 | August 30, 2024 | August 07, 2024 |
| $0.08 | $0.08 | May 10, 2024 | May 13, 2024 | May 24, 2024 | May 01, 2024 |
| $0.08 | $0.08 | February 09, 2024 | February 12, 2024 | February 26, 2024 | February 01, 2024 |
| $0.08 | $0.08 | November 09, 2023 | November 10, 2023 | November 24, 2023 | October 31, 2023 |
| $0.08 | $0.08 | August 17, 2023 | August 18, 2023 | September 01, 2023 | August 08, 2023 |
| $0.08 | $0.08 | May 12, 2023 | May 15, 2023 | May 26, 2023 | May 03, 2023 |
| $0.08 | $0.08 | February 10, 2023 | February 13, 2023 | February 27, 2023 | February 02, 2023 |
| $0.32 | $0.08 | November 10, 2022 | November 14, 2022 | November 28, 2022 | November 01, 2022 |
| $0.32 | $0.08 | August 12, 2022 | August 15, 2022 | August 29, 2022 | August 04, 2022 |
| $0.32 | $0.08 | May 13, 2022 | May 16, 2022 | May 27, 2022 | May 04, 2022 |
| $0.32 | $0.08 | February 10, 2022 | February 11, 2022 | February 25, 2022 | February 01, 2022 |
| $0.32 | $0.08 | November 10, 2021 | November 12, 2021 | November 26, 2021 | November 02, 2021 |
| $0.32 | $0.08 | August 13, 2021 | August 16, 2021 | August 27, 2021 | August 05, 2021 |
| $0.32 | $0.08 | May 14, 2021 | May 17, 2021 | May 28, 2021 | May 06, 2021 |
| $0.32 | $0.08 | February 11, 2021 | February 12, 2021 | February 26, 2021 | February 02, 2021 |
| $0.32 | $0.08 | November 13, 2020 | November 16, 2020 | November 27, 2020 | November 05, 2020 |
| $0.32 | $0.08 | August 17, 2020 | August 18, 2020 | August 28, 2020 | August 04, 2020 |
| $0.32 | $0.08 | May 08, 2020 | May 11, 2020 | May 22, 2020 | April 30, 2020 |
Bio-Techne News
Read the latest news about Bio-Techne, including recent articles, headlines, and updates.
Merger between CMB.TECH and Golden Ocean
Antwerp, April 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) (“Golden Ocean”) are pleased to announce that they have signed a term sheet (the “Term Sheet”) for a contemplated stock-for-stock merger, with CMB.TECH as the surviving entity, based on an exchange ratio of 0.95 shares of CBM.TECH for each share of Golden Ocean (the “Exchange Ratio”), subject to customary adjustments. The Term Sheet has been unanimously approved by CMB.TECH's Supervisory Board and by Golden Ocean's Board of Directors, including its special transaction committee composed of disinterested directors (the “Transaction Committee”). As part of this, the Transaction Committee has received a fairness opinion from its financial advisor DNB Markets, part of DNB Bank ASA, concluding that the Exchange Ratio is fair from a financial point of view to Golden Ocean's shareholders. The transaction would be structured as a merger with Golden Ocean merging with and into CMB.TECH Bermuda Ltd., a wholly-owned subsidiary of CMB.TECH (the “Merger”). Existing shares of Golden Ocean, which are not (directly or indirectly) owned by CMB.TECH, will be cancelled and ultimately exchanged for newly issued CMB.TECH shares at an exchange ratio of 0.95 shares of CBM.TECH for each share of Golden Ocean, subject to customary adjustments, including to reflect share buybacks, share issuances and/or dividend distributions that may take place prior to completion of the Merger. Upon completion of the Merger, 95,952,934 new shares of CMB.TECH would be issued, whereby CMB.TECH shareholders would own approximately 70% of the total issued share capital of the combined company (or 67% excluding treasury shares) and Golden Ocean shareholders would own approximately 30% (or 33% excluding treasury shares), assuming the Exchange Ratio is not adjusted.
Cycurion, Inc. Announces Expansion into Latin America Through Partnership with LSV-TECH International of Colombia
Partnership Extends Cycurion's Sales Presence Into 135 Countries via LSV's Strategic Partnership with Nokia Partnership Extends Cycurion's Sales Presence Into 135 Countries via LSV's Strategic Partnership with Nokia
CMB.TECH - General meetings of 22 May 2025
Antwerp, April 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) invites its shareholders to participate in the Annual General Meeting, Special General Meeting & Extraordinary General Meeting that will be held on Thursday 22 May 2025 at 10.00 a.m. CET in 2000 Antwerp, De Gerlachekaai 20.
CYBER ENVIRO-TECH SECURES REGISTRATION WITH KUWAIT OIL COMPANY - POTENTIAL PROJECT VALUE OVER $100 MILLION ANNUALLY
SCOTTSDALE, Ariz. , April 17, 2025 /PRNewswire/ -- Cyber Enviro-Tech, Inc. (OTCQB-CETI) today announced its successful registration with Kuwait Oil Company (KOC), the world's 10th largest oil producer.
Fortescue and CMB.TECH sign agreement for ammonia-powered ore carrier
Antwerp, April 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) has signed an agreement with Fortescue to charter a new ammonia-powered vessel. This emphasises the commitment of both companies to decarbonise the shipping industry. This 210,000-dwt ammonia-powered Newcastlemax will feature a dual fuel engine and is expected to be delivered by the end of 2026.
CMB.TECH publishes its annual report and submits Form 20-F for the year ended 31 December 2024
Antwerp, April 10, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) published its annual report in accordance with Belgian law for the year ended on 31 December 2024 on the Company's website in the “Investors” section under “Annual and financial reports”.
Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument
MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research.
CMB.TECH announces final year results
CMB.TECH ANNOUNCES FINAL YEAR RESULTS TRANSFORMATIONAL YEAR AND STRONG EARNINGS ANTWERP, Belgium, 27 March 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its final financial results today for the full year ended 31 December 2024. HIGHLIGHTS 2024 Profit of USD 93.1 million in Q4 2024 bringing full year profit to USD 870.8 million Total contract backlog increased to USD 2.94 billion Name change from Euronav to CMB.TECH (ticker symbol CMBT) CMB.TECH focused on its fleet rejuvenation with 21 newbuild deliveries Further fleet expansion with 1 container vessel, 2 dry bulk carriers, 2 product tankers, 6 chemical tankers and 2 CTVs contracted in 2024 & Q1 2025 Sale of 6 older Suezmaxes, 4 older VLCCs and 1 container vessel New hydrogen engine R&D Center in Japan Sale of Euronav Ship Management Hellas (ESMH) to Anglo- Eastern Univan Group HIGHLIGHTS Q1 2025 CMB.TECH joins forces with MOL to jointly own and charter a total of 9 ammonia-fuelled vessels Share purchase agreement with Hemen Holding Limited for the acquisition of 81,363,730 shares in Golden Ocean Group Limited For the fourth quarter of 2024, the company realised a net gain of USD 93.1 million or USD 0.48 per share (fourth quarter 2023: a net gain of USD 406.6 million or USD 2.01 per share).
Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany
MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including: The recently launched Leo™ System, powered by Simple Western™ Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA.
CMB.TECH and MOL sign landmark agreement for nine ammonia-powered vessels
Antwerp, March 24, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) is pleased to announce that it has signed an agreement with Mitsui O.S.K. Lines, Ltd. (“MOL”) and MOL CHEMICAL TANKERS PTE. LTD. (“MOLCT”) for nine ammonia-powered vessels. These vessels will be among the world's first ammonia-powered Newcastlemax bulk carriers and chemical tankers. The delivery of these ships is expected between 2026 and 2029.
Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System
MINNEAPOLIS , March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation.
Hemen sells stake in Golden Ocean to CMB.TECH
Limassol, Cyprus, March 4, 2025 – Hemen Holding Limited (“Hemen”) today announced that it has entered into an agreement to sell 81,363,730 shares in Golden Ocean Group Limited (NASDAQ/OSE: GOGL) (the "Company" or "Golden Ocean") to CMB.TECH (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH”), for a total consideration of approximately USD 1,179 million (the “Transaction”). The shares represent ca. 40.8%1 of Golden Ocean's outstanding shares and votes and includes all Hemen's shares in the Company.
CMB.TECH acquires Hemen's shares in Golden Ocean – Disclosure of large shareholdings
ANTWERP, Belgium, 4 March, 2025 - CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH”) today announced that it, through its wholly-owned subsidiary, CMB.TECH Bermuda Ltd., has entered into a share purchase agreement with Hemen Holding Limited (“Hemen”), for the acquisition of 81,363,730 shares in Golden Ocean Group Limited (“Golden Ocean”) at a price of 14.49 USD per share (the “Transaction”). The shares represent approx. 40.4% of Golden Ocean's issued share capital (calculated on the basis that Golden Ocean has issued 201,165,621 shares) and approx. 40.8% of Golden Ocean's outstanding shares with voting rights (calculated on the basis that Golden Ocean has 1,787,328 treasury shares which are excluded from voting on). CMB.TECH did not own any shares or right to shares in Golden Ocean prior to the Transaction.
CMB.TECH buys Hemen stake in Golden Ocean
Belgium, March 04, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) is pleased to announce that it has entered into a share purchase agreement with Hemen Holding Limited (“Hemen”), for the acquisition of 81,363,730 shares in Golden Ocean Group Limited (“Golden Ocean”) (NASDAQ: GOGL & Euronext: GOGL) (representing ca. 40.8%[1] of Golden Ocean's outstanding shares and votes which includes all Golden Ocean shares controlled by Hemen), at a price of 14.49 USD per share (the “Transaction”).
Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes
AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes. MINNEAPOLIS and OXFORD, England , March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX® Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research.
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss.
Bio-Techne to Present at Investor Conferences
MINNEAPOLIS , Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference March 4, 2025 2:30 PM EST Leerink Partners Global Healthcare Conference March 11, 2025 11:20 AM EDT Barclays 27th Annual Global Healthcare Conference March 12, 2025 10:00 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
CMB.TECH announces Q4 2024 results
CMB.TECH ANNOUNCES Q4 2024 RESULTS STRONG RESULTS DESPITE SLOW MARKETS ANTWERP, Belgium, 27 February 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the fourth quarter ended 31 December 2024. HIGHLIGHTS Profit of USD 93.1 million in Q4 2024 bringing YTD profit to USD 870.8 million Delivery of 7 newbuilding vessels Sale of 4 Suezmaxes Selena (2007, 150,205 dwt), Cap Victor (2007, 158,853 dwt), Cap Felix (2008, 158,765 dwt) & Cap Lara (2007, 158,826 dwt) Sale of Windcat 6 For the fourth quarter of 2024, the company realised a net gain of USD 93.1 million or USD 0.48 per share (fourth quarter 2023: a net gain of 406.6 USD million or USD 2.01 per share).
YSX TECH. CO. LTD Announces Unaudited Financial Results for the Six Months Ended September 30, 2024
GUANGZHOU, China, Feb. 24, 2025 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced its unaudited financial results for the six months ended September 30, 2024.
Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
MINNEAPOLIS , Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.
Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
MINNEAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types.
CMB.TECH announces Q4 2024 results on 27/02/2025
Antwerp, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its fourth quarter 2024 earnings prior to market opening on Thursday 27 February 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TECH.